Table 1.
Characteristics of OPC patients with HPV-positive, HPV-negative and HPV-unknown tumors from 2010 to 2014.
| OPCs included in analysis of HPV tumor status 2010–2014 | |||||
|---|---|---|---|---|---|
| Characteristic | Total No. (%)a | HPV-positive No. (%)a | HPV-negative No. (%)a | HPV-unknown No. (%)a | p-valueb |
| Total | 63,187 | 21,880 (35) | 11,504 (18) | 29,803 (47) | |
| Age in years, mean (SD) | 60.5 (10.2) | 58.8 (9.5) | 61.1 (10.5) | 61.6 (10.5) | <0.001 |
| Sex | <0.001 | ||||
| Male | 51,248 (81) | 13,729 (86) | 8752 (76) | 23,767 (80) | |
| Female | 11,939 (19) | 3151 (14) | 2752 (24) | 6036 (20) | |
| Race | <0.001 | ||||
| White | 55,922 (89) | 20,316 (93) | 9760 (85) | 25,846 (87) | |
| Black | 5498 (9) | 1030 (5) | 1380 (12) | 3088 (10) | |
| Other/unknown | 1767 (3) | 534 (2) | 364 (3) | 869 (3) | |
| Residence | <0.001 | ||||
| Metro | 51,144 (81) | 18,032 (82) | 9561 (83) | 23,551 (79) | |
| Urban | 9,357 (15) | 2975 (14) | 1514 (13) | 4868 (16) | |
| Rural | 1075 (2) | 347 (2) | 140 (1) | 588 (2) | |
| Unknown | 1611 (3) | 526 (2) | 289 (3) | 796 (3) | |
| Facility type | <0.001 | ||||
| Community cancer program | 5671 (9) | 1529 (7) | 968 (9) | 3174 (11) | |
| Comprehensive community cancer program | 22,858 (37) | 6934 (32) | 3948 (35) | 11,976 (41) | |
| Academic /research | 27,335 (44) | 10,598 (49) | 5179 (46) | 11,558 (39) | |
| Integrated network | 6529 (10) | 2473 (11) | 1243 (11) | 2813 (10) | |
| Insurance | <0.001 | ||||
| Not insured | 3424 (5) | 839 (4) | 683 (6) | 1902 (6) | |
| Private | 29,579 (47) | 13,125 (60) | 4877 (42) | 11,577 (39) | |
| Medicare, Medicaid, other government | 28,235 (45) | 7645 (35) | 5744 (50) | 14,846 (50) | |
| Unknown | 1953 (3) | 271 (1) | 201 (2) | 1481 (5) | |
| Charleson-Deyo Score | <0.001 | ||||
| 0 | 51,359 (81) | 18,324 (84) | 9097 (79) | 23,938 (80) | |
| 1 | 9144 (14) | 2834 (13) | 1838 (16) | 4472 (15) | |
| 2+ | 2684 (4) | 722 (3) | 569 (5) | 1393 (5) | |
| Year of diagnosis | <0.001 | ||||
| 2010 | 11,261 (18) | 2111 (10) | 1326 (12) | 7824 (26) | |
| 2011 | 12,154 (19) | 3340 (15) | 2154 (19) | 6660 (22) | |
| 2012 | 12,637 (20) | 4622 (21) | 2518 (22) | 5497 (18) | |
| 2013 | 13,356 (21) | 5524 (25) | 2710 (24) | 5122 (17) | |
| 2014 | 13,779 (22) | 6283 (29) | 2796 (24) | 4700 (16) | |
| Primary subsite | <0.001 | ||||
| Tonsil | 28,866 (46) | 11,902 (54) | 4839 (42) | 12,125 (41) | |
| Tongue base | 25,249 (40) | 8435 (39) | 4470 (39) | 12,344 (41) | |
| Other oropharynx | 9072 (14) | 1543 (7) | 2195 (19) | 5334 (18) | |
| Clinical T stagec | <0.001 | ||||
| T1 | 13,642 (22) | 5558 (25) | 2320 (20) | 5764 (19) | |
| T2 | 21,479 (34) | 8190 (37) | 3734 (32) | 9555 (32) | |
| T3 | 10,374 (16) | 3131 (14) | 2154 (19) | 4089 (17) | |
| T4 | 9111 (14) | 2192 (10) | 2000 (17) | 4919 (17) | |
| Unknown | 8585 (14) | 2809 (13) | 1297 (11) | 4479 (15) | |
| Clinical N stagec | <0.001 | ||||
| N0 | 13,034 (21) | 2979 (14) | 3069 (27) | 6986 (23) | |
| N1 | 19,392 (31) | 12,728 (58) | 1872 (16) | 4792 (16) | |
| N2 | 22,567 (36) | 2892 (13) | 5187 (45) | 14,488 (49) | |
| N3 | 3145 (5) | 802 (4) | 823 (7) | 1520 (5) | |
| Unknown | 5050 (8) | 2479 (11) | 554 (5) | 2017 (7) | |
| Clinical M stagec | <0.001 | ||||
| M0 | 56,266 (89) | 20,196 (92) | 10,139 (88) | 25,931 (87) | |
| M1 | 2226 (4) | 435 (2) | 436 (4) | 1355 (5) | |
| Unknown | 4695 (7) | 1249 (6) | 929 (8) | 2517 (8) | |
| Treatment | <0.001 | ||||
| Surgery | 6910 (11) | 1861 (9) | 1539 (13) | 3510 (12) | |
| Surgery + radiation | 4955 (8) | 2327 (11) | 844 (7) | 1784 (6) | |
| Surgery + chemoradiation | 10,739 (17) | 5134 (23) | 1802 (16) | 3803 (13) | |
| Radiation | 4743 (8) | 1315 (6) | 904 (8) | 2524 (8) | |
| Chemoradiation | 28,594 (45) | 10,006 (46) | 5024 (44) | 13,564 (46) | |
| Palliative only | 1266 (2) | 253 (1) | 282 (2) | 731 (2) | |
| Other/unknown | 5984 (9) | 984 (5) | 1110 (10) | 3890 (13) | |
Abbreviations: HPV, human papillomavirus; OPC, oropharyngeal cancer; SD, standard deviation; No., number.
a
Percentages may not sum to 100% because of rounding.
b
p-values were calculated using t-test for age, and chi2 tests for other variables.
c
American Joint Committee on Cancer Eighth Edition clinical staging was used for HPV-positive and HPV-negative tumors, but Seventh Edition staging was used for HPV-unknown tumors because Eighth Edition requires known HPV tumor status.